drugset / Trial / NCT04135820

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

NCT04135820

Phase 1 Completed 16 enrolled Beta Pharma, Inc.
RandomizedCrossoverOpen-labelOther

Summary

This is an open-label, randomised, single-dose, cross-over phase I study to evaluate the effect of food on the pharmacokinetic profile of BPI-7711 in Chinese healthy male subjects.

Timeline

Start
2019-12-17
Primary completion
2020-03-25
Completion
2020-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject rezivertinib Small molecule 180 mg